Latest Breaking News On - Hiroki yukami - Page 1 : comparemela.com

Uncertainty Surrounds Sensitivity of ctDNA in CRC

ctDNA is a useful prognostic tool in CRC, but it's unclear whether it can guide the use of adjuvant chemotherapy.

United statesMemorial sloan kettering cancer centerNew yorkDavid ellisonAparna raj parikhHiroki yukamiEujung kimHarvard medical schoolPeter maccallum cancer centrePashtoon murtaza kasiWeill cornell medicineJeannie tieRaj parikhNot sensitiveColorectal cancerColorectal cancer crc

Circulating tumor DNA detection may predict treatment outcomes in colorectal cancer

Circulating tumor DNA detection may predict treatment outcomes in colorectal cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesHiroki yukamiMindy valcarcelBrettl eckerBymatthew shinkleCancers symposiumOsaka medicalPharmaceutical university

Liquid Biopsy Has Mixed Performance for Predicting Colon Cancer Outcomes

Adjuvant chemo fails to move needle on DNA clearance, but dynamics predictive of DFS

United statesNatera signateraAparna parikhCharles bankheadVank morrisHiroki yukamiCancer centerMd anderson cancer centerGastrointestinal cancersOsaka medicalPharmaceutical universityMass general cancer centerMedpage today

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera s Clinical Utility in CRC -January 18, 2024 at 08:08 am EST

Oral presentations include updated 24-month DFS analysis from GALAXY and first interim analysis from BESPOKE CRC .

United statesSan carlosSan franciscoGiulia maddalenaSakti chakrabartiAndrew pellattJin choiMasaaki miyoHiroki yukamiNikolas naleidHidekazu oyoshiUjwal yanalaCancer chemotherapy centerAmerican society of clinical oncologyNatera incClinical laboratory improvement amendments

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera s Clinical Utility in CRC Seite 1

18.01.2024 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical . Seite 1

United statesSan franciscoHiroki yukamiAmerican society of clinical oncologyNatera incAmerican societyClinical oncologyCancers symposiumNatera chartAtera kursAtera aktie